Martin Heidecker
Chief Investment Officer at AMR Action Fund
Cambridge, Massachusetts
Overview
Work Experience
Chief Investment Officer
2021 - Current
Member Board of Directors AMR action
2020 - 2021
AMR Action Fund renders investment, healthcare, biotech, research and development, pharmaceutical, and antibiotic services.
Board Member MassBio Biotechnology
2020
Member Board of Directors Libra Therapeutics Inc.
2020 - 2021
Libra Therapeutics is a biotechnology company.
Raised $29,000,000.00 from Yonjin Venture, Sante Ventures, Dolby Family Ventures, Sixty Degree Capital, Epidarex Capital and Boehringer Ingelheim Venture Fund.
Member Board of Directors Tiga Tx Inc.
2020 - 2021
Member Board of Directors Rgenta Therapeutics Inc.
2020 - 2021
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.
Raised $116,949,198.00 from Highlight Capital, The Leukemia & Lymphoma Society’s Therapy Acceleration Program, Legend Star, CICC, Delos Capital, Lilly Asia Ventures, Vivo Capital, Korean Investment Partners, Boehringer Ingelheim Venture Fund and AstraZeneca.
Member Board of Directors Abexxa Biologics Inc.
2016 - 2021
Member Board of Directors
2015 - 2021
Managing Director BIVF USA Inc.
2013 - 2021
Run Boehringer Ingelheim Venture Fund offices in the United States, scout for early investment opportunities in Cambridge and other sites of innovation and lead respective Due Diligence, invest in start-up biotech companies and represent BIVF US as a Board Director.
Member Board of Directors
2012 - 2020
ArmaGen is focused on developing technologies for siRNA delivery across the blood-brain barrier.
Raised $35,492,898.00 from Shire, Takeda Ventures, Mitsui Global Investment and Boehringer Ingelheim Venture Fund.
Member Board of Directors
2014 - 2016